BioSpace News Archive

Geron Corporation, a late-stage clinical biopharmaceutical company, announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the unveiling of its technology platform NULISA™, a novel automated ultrasensitive and highly multiplexed proteomics technology for liquid biopsy.

Sivananthan Laboratories Inc., a high-tech business incubator and a national leader in the infrared sensing and imaging industry, announced the successful completion of a $1.5M award from the Small Business Technology Transfer Phase II program for the development of an entangled short-wavelength infrared photon source.

Reaction Biology (“Reaction” or the “Company”) today announced that eleven abstracts highlighting data from the Company’s expanding suite of research offerings will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, 2023, in Orlando, Florida.

Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company) today announces that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its new canaloplasty device, iTrack™ Advance.

Initial offerings focus on high-content imaging and digital PCR Agathos Biologics, a leading biotechnology company, is proud to offer advanced analytical testing services for life science researchers.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the Board of Directors has proposed Ms.

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.

10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023.

Oncocyte Corporation, a precision diagnostics company, announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024.